What is the best treatment option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma (mRCC) patients (pts): TKI-TKI or TKI-mTORi? A European retrospective study.

Reza-Thierry Elaidi, Benoit Beuselinck, Agnes Maj-HES, Delphine Carmier, Aristotelis Bamias, Philip R. Debruyne, Camillo Porta, Sophie Roca, Stephane Oudard

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)375-375
JournalJournal of Clinical Oncology
Volume30
Issue number5_suppl
DOIs
Publication statusPublished - 10 Feb 2012
Externally publishedYes

Cite this